Category - Developments

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Developments

Quoin reports positive interim data from study of topical treatment for NS

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome (NS), a rare, genetic skin disease...

August 28, 2026

Developments

BrainsWay Deep TMS study shows 70% reduction in suicidal ideation in MDD

BrainsWay (NASDAQ: BWAY; TASE: BWAY) has announced the publication of new peer-reviewed data in the Journal of Affective Disorders demonstrating significant reductions in suicidal ideation among patients with major...

August 27, 2026

Developments

Precision doses first patient in study of in vivo gene editing program in DMD

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of...

August 25, 2026

Developments

RMTG’s Cellgenic launches NK cell product line outside U.S.

Regenerative Medical Technology Group (RMTG) (OTCID: RMTG) has announced that its Cellgenic division has launched a natural killer (NK) cell product line for permitted markets outside the U.S., with an initial...

August 25, 2026

Developments

VERAXA and Secarna report positive results from AOC research collaboration

VERAXA Biotech (NASDAQ: VRXA) and closely held Secarna Pharmaceuticals have announced positive initial results from their research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for...

August 25, 2026

Developments

Oculis treats first patient in trial of Privosegtor in ON

Oculis Holding (NASDAQ: OCS; XICE: OCS) has announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON). According to Oculis...

August 25, 2026

Developments

Activist hedge fund, Kaos Capital, calls for a Capricor Therapeutics strategic shift

Kaos Capital today issued a letter to its fellow Capricor Therapeutics (NASDAQ: CAPR) shareholders calling on them to support an immediate meeting with the Board of Directors regarding the Company’s future strategic...

August 21, 2026

Developments

Niagen expands Tru Niagen retail footprint

Niagen Bioscience (NASDAQ: NAGE) has announced that Tru Niagen, the company’s healthy-aging coenzyme nicotinamide adenine dinucleotide (NAD+)-boosting supplement, is now available at U.S. GNC and Sam’s Club retail...

August 20, 2026

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Category - Developments

Subscribe